CLYM 8-K 2026-11-05

Climb Bio, Inc. (CLYM) 8-K dated 2026-11-05 — accession 0001193125-26-448556.

Climb Bio, Inc. (CLYM) is a biotechnology company listed on US.

Climb Bio, Inc. filed a 8-K on 2026-11-05. Accession 0001193125-26-448556.

This 8-K covers: Results of operations (Item 2.02), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported CLYM revenue for 2024-12-31 was $8.1M. Net income was -$73.9M. Revenue was up 76.0% from 2023-12-31 to 2024-12-31. CLYM currently screens at market cap $85.8M.

Not investment advice. The CLYM SEC hub lists recent forms. The stock page is the research view.